Read news about breast cancer from Duke Cancer Institute.
High Cholesterol Fuels the Growth and Spread of Breast Cancer (DukeHealth.org)
Nov. 29, 2013
A byproduct of cholesterol functions like the hormone estrogen to fuel the growth and spread of the most common types of breast cancers, researchers at the Duke Cancer Institute report.
Oral Drug May Improve Survival in Men with Metastatic Prostate Cancer (DukeHealth.org)
Nov. 19, 2013
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
New prognostic model predicts survival in advanced prostate cancer (DukeHealth.org)
Oct. 18, 2013
For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.
James Abbruzzese selected Chief of Duke Division of Medical Oncology
Oct. 9, 2013
James Abbruzzese, MD, named Chief of the Duke Division of Medical Oncology and Associate Director for Clinical Research for the Duke Cancer Institute.
Thomas and Janet Kean, Nick Valvano to Receive Duke’s Shingleton Award (DukeHealth.org)
Sept. 26, 2013
The Duke Cancer Institute has named Thomas and Janet Kean of Norwood, N.C., and Nick Valvano of Cary, N.C., president emeritus of The V Foundation for Cancer Research, as the 2013 recipients of the Shingleton Award. The award recognizes the outstanding service and generosity of individuals who are committed to the war against cancer.
Spinal Fusion Material, BMP, Increases Risk of Benign Tumors, Not Cancer (DukeHealth.org)
Sept. 5, 2013
Using a certain bone grafting material for spinal fusion, one of the most common procedures for people with painful vertebral deteriorations, does not appear to result in higher rates of cancer, according to researchers at Duke Medicine.
Osteoporosis Drug Stops Growth of Breast Cancer Cells, Even in Resistant Tumors (DukeHealth.org)
June 15, 2013
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.
Doctors should discuss financial concerns of cancer patients (DukeHealth.org)
May 16, 2013
Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report.
Duke researchers describe how breast cancer cells acquire drug resistance (DukeHealth.org)
May 7, 2013
A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute.
Cancer studies often lack necessary rigor to answer key questions (DukeHealth.org)
Apr. 29, 2013
Fueled in part by an inclination to speed new treatments to patients, research studies for cancer therapies tend to be smaller and less robust than for other diseases.